Casapao Anthony M, Davis Susan L, McRoberts John Paul, Lagnf Abdalhamid M, Patel Sonal, Kullar Ravina, Levine Donald P, Rybak Michael J
Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA Department of Pharmacy Services, Henry Ford Hospital, Detroit, Michigan, USA.
Antimicrob Agents Chemother. 2014 Aug;58(8):4636-41. doi: 10.1128/AAC.02820-13. Epub 2014 Jun 2.
Infective endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA IE) is associated with high morbidity and mortality. Vancomycin continues to be the primary treatment for this disease. The emergence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA), defined as a modified population analysis profile (PAP) of ≥ 0.9, may affect patient outcomes. The objective of this study was to evaluate the relationship of vancomycin subpopulation susceptibility and the clinical outcomes of MRSA IE. We conducted a retrospective cohort study of patients treated with vancomycin for MRSA IE from 2002 to 2013 at the Detroit Medical Center. A modified PAP was used to measure the vancomycin PAP MIC and the PAP-to-area under the curve (AUC) ratio. Treatment failure was defined as bacteremia for ≥ 7 days or death attributed to MRSA. Classification and regression tree (CART) analysis was used to select a failure breakpoint between the PAP-AUC ratios and the PAP MIC. A total of 202 patients were included in the study. Twenty-seven percent of the patients had left-sided IE, 19% of the strains were hVISA, and 70% of the strains were staphylococcal cassette chromosome mec element (SCCmec) type IV. Overall treatment failure was observed in 64%; 59% had persistent bacteremia, and the 30-day attributable mortality rate was 21%. The CART breakpoint between failure and success in terms of the PAP-AUC ratio was 0.9035. On logistic regression analysis, intensive care unit (ICU) admission (adjusted odds ratio [aOR], 2.8; 95% confidence interval [CI], 1.5 to 5.2) and a PAP MIC of ≥ 4 mg/liter (aOR, 3.2; 95% CI, 1.3 to 8.4) were associated with failure (P = 0.001 and 0.015, respectively). A PAP MIC of ≥ 4 mg/liter and ICU admission were significant for treatment failure for patients with MRSA IE. The PAP-AUC ratio of ≥ 0.9035 predicted failure consistent with the hVISA definition. The role of population MIC analysis in predicting outcome with MRSA infections warrants further investigation.
耐甲氧西林金黄色葡萄球菌引起的感染性心内膜炎(MRSA IE)与高发病率和高死亡率相关。万古霉素仍然是该病的主要治疗药物。异质性万古霉素中介金黄色葡萄球菌(hVISA)的出现,定义为改良群体分析谱(PAP)≥0.9,可能会影响患者的预后。本研究的目的是评估万古霉素亚群敏感性与MRSA IE临床结局之间的关系。我们对2002年至2013年在底特律医疗中心接受万古霉素治疗的MRSA IE患者进行了一项回顾性队列研究。采用改良的PAP来测量万古霉素PAP MIC以及PAP与曲线下面积(AUC)的比值。治疗失败定义为菌血症持续≥7天或因MRSA导致的死亡。使用分类与回归树(CART)分析来选择PAP - AUC比值和PAP MIC之间的失败断点。共有202例患者纳入研究。27%的患者患有左侧心内膜炎,19%的菌株为hVISA,70%的菌株为葡萄球菌盒式染色体mec元件(SCCmec)IV型。总体治疗失败率为64%;59%的患者有持续性菌血症,30天归因死亡率为21%。在PAP - AUC比值方面,失败与成功之间的CART断点为0.9035。经逻辑回归分析,入住重症监护病房(ICU)(调整后的优势比[aOR],2.8;95%置信区间[CI],1.5至5.2)以及PAP MIC≥4 mg/L(aOR,3.2;95% CI,1.3至8.4)与治疗失败相关(P分别为0.001和0.015)。对于MRSA IE患者,PAP MIC≥4 mg/L和入住ICU对治疗失败具有显著意义。PAP - AUC比值≥0.9035预测失败与hVISA定义一致。群体MIC分析在预测MRSA感染结局中的作用值得进一步研究。